We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
01 May 2019
On 28 February 2019 Health Canada released a Notice to Industry: Health Canada and CADTH launch new initiative to provide early parallel scientific advice. Currently, Health Canada and the Canadian Agency for Drugs and Technologies in Health (CADTH) offer separate processes for drug sponsors seeking early advice on evidence relating to market authorisation and reimbursement in Canada. Through this new initiative, drug sponsors can obtain advice from Health Canada and the CADTH in parallel.
The initiative will enable Health Canada and the CADTH to collaborate and share perspectives while each formulating independent advice regarding a sponsor's specific drug development plan. It will also give sponsors the opportunity to have a joint meeting with Health Canada and the CADTH to discuss their advice. The initiative will:
Early parallel scientific advice can be sought on topics such as:
New drug products, existing drug products with new indications, drugs for rare diseases and oncology products are all eligible for the initiative. According to the notice, early parallel scientific advice is most beneficial for:
Applications must be filed early in the drug development cycle, when adjustments to protocols for pivotal trials are still feasible. Drug sponsors that are interested in participating in this initiative should contact the CADTH.
For further information on this topic please contact Tierney GB Deluzio at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.